Patents by Inventor Peter John Hudson
Peter John Hudson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11400145Abstract: The present invention relates generally to a population of stem cells (e.g., iPSCs or HSCs) that comprise nucleic acids encoding a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, for example two distinct tumour antigenic determinants. The present invention is also directed to a population of T cells that co-express a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, such as two distinct tumour antigenic determinants. The cells of the present invention can be derived from chosen donors whose HLA type is compatible with significant sectors of the populations, and are useful in a wide variety of applications, in particular in the context of the therapeutic treatment of neoplastic conditions.Type: GrantFiled: November 23, 2016Date of Patent: August 2, 2022Assignee: CARTHERICS PTY. LTD.Inventors: Richard Boyd, Alan Trounson, Hiroshi Kawamoto, Peter John Hudson, Runzhe Shu
-
Publication number: 20120164068Abstract: The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region 1 such that if at least two of the cysteine residues are not conjugated to another compound a disulphide bond forms between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides a protein that binds to TAG72. The present invention also provides conjugates of the protein and another compound.Type: ApplicationFiled: July 2, 2010Publication date: June 28, 2012Inventors: Peter John Hudson, Paul Robert Sanders, Debra Tamvakis, Fabio Turatti, Michael Paul Wheatcroft, David Leong
-
Publication number: 20080312102Abstract: The present invention relates a method of generating modified binding moieties comprising a cytokine binding domain consisting of a first FmIII-like domain and a second FnIII-like domain in which at least one amino acid residue within the cytokine binding domain in modified such that the binding characteristics of the cytokine binding domain are altered, and/or, the solubility and/or stability of the binding moiety is improved.Type: ApplicationFiled: December 16, 2004Publication date: December 18, 2008Applicant: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Joseph Noozhumutry Varghese, Peter John Hudson, Barbara Elaine Power
-
Publication number: 20080305988Abstract: The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the modified VLD is improved when compared with the unmodified VLD.Type: ApplicationFiled: May 15, 2008Publication date: December 11, 2008Inventors: Gregory Coia, Maria Galanis, Peter John Hudson, Robert Alexander Irving, Stewart Douglas Nuttall
-
Patent number: 7405288Abstract: The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the modified VLD is improved when compared with the unmodified VLD.Type: GrantFiled: October 27, 2006Date of Patent: July 29, 2008Assignee: Diatech Pty. Ltd.Inventors: Maria Galanis, Peter John Hudson, Robert Alexander Irving, Stewart Douglas Nuttall
-
Patent number: 7166697Abstract: The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterized in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the modified VLD is improved when compared with the unmodified VLD.Type: GrantFiled: March 5, 1999Date of Patent: January 23, 2007Assignee: Diatech Pty. Ltd.Inventors: Maria Galanis, Peter John Hudson, Robert Alexander Irving, Stewart Douglas Nuttall
-
Publication number: 20040071690Abstract: This invention provides polyvalent or polyspecific protein complexes, comprising three or more polypeptides which associate to form three or more functional target-binding regions (TBRs), and in which each individual polypeptide comprises two or more immunoglobulin-like domains which are covalently joined together, such that two Ig-like domains in a single polypeptide do not associate with each other to form a TBR. By using a linker peptide of fewer than three amino acid residues the immunoglobulin-like domains of the individual polypeptides are prevented from associating, so that complex formation between polypeptides is favoured. Preferably the polyvalent or polyspecific protein is a trimer or tetramer. The proteins of the invention have specificities which may be the same or different, and are suitable for use as therapeutic, diagnostic or imaging agents.Type: ApplicationFiled: February 19, 2003Publication date: April 15, 2004Applicant: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATIONInventors: Peter John Hudson, Alex Andrew Kortt, Robert Alexander Irving, John Leslie Atwell
-
Publication number: 20030170820Abstract: Provided is a method for the mutation, synthesis and selection of a protein of interest, by first incubating a replicable RNA molecule encoding the protein with ribonucleoside triphosphate precursors of RNA and an RNA-directed RNA polymerase, such that the RNA-directed RNA polymerase replicates the RNA molecule but introduces mutations thereby generating a population of a mutant RNA molecules. The mutant RNA molecules are then incubated with a translation system under conditions which result in the synthesis of a population of mutant proteins. After translation, the mutant proteins are linked to their encoding RNA molecules, and one or more mutant proteins of interest are selected.Type: ApplicationFiled: April 7, 2003Publication date: September 11, 2003Inventors: Gregory Coia, Peter John Hudson, Peter Iliades, Robert Alexander Irving
-
Patent number: 6562622Abstract: The present invention provides a method for the mutation, synthesis and selection of a protein which binds to a target molecule, the method comprising: (a) incubating a replicable mRNA molecule encoding the protein with ribonucleoside triphosphate precursors of RNA and an RNA-directed RNA polymerase, wherein the RNA-directed RNA polymerase replicates the mRNA molecule but introduces mutations thereby generating a population of mutant mRNA molecules; (b) incubating the mutant mRNA molecules from step (a) with a translation system under conditions which results in the synthesis of population of mutant proteins such that after translation, mutant proteins are linked to their encoding mRNA molecules thereby forming a population of mutant proteins such that after translation, mutant proteins are linked to their encoding mRNA molecules thereby forming a population of mutant/mRNA complexes; (c) selecting one or more mutant protein/mRNA complex(es) by exposing the population of mutant protein/mRNA complexes from stepType: GrantFiled: December 11, 2000Date of Patent: May 13, 2003Assignee: Diatech PTY, LTDInventors: Gregory Coia, Peter John Hudson, Peter Iliades, Robert Alexander Irving
-
Publication number: 20020018749Abstract: This invention provides polyvalent or polyspecific protein complexes, comprising three or more polypeptides which associate to form three or more functional target-binding regions (TBRs), and in which each individual polypeptide comprises two or more immunoglobulin-like domains which are covalently joined together, such that two Ig-like domains in a single polypeptide do not associate with each other to form a TBR. By using a linker peptide of fewer than three amino acid residues the immunoglobulin-like domains of the individual polypeptides are prevented from associating, so that complex formation between polypeptides is favoured. Preferably the polyvalent or polyspecific protein is a trimer or tetramer. The proteins of the invention have specificities which may be the same or different, and are suitable for use as therapeutic, diagnostic or imaging agents.Type: ApplicationFiled: March 5, 1999Publication date: February 14, 2002Inventors: PETER JOHN HUDSON, ALEX ANDREW KORTT, ROBERT ALEXANDER IRVING, JOHN LESLIE ATWELL
-
Patent number: 6054126Abstract: This invention relates to the cloning and characterization of the infectious bursal disease virus (IBDV) genome, to the identification of cloned genes for host-protective antigens of IBDV, to the expression of cDNA inserts encoding the whole or part of host-protective antigens of IBDV in E.coli or other host cells, and to the use of the expressed antigens in the production of virus neutralizing antibodies in chickens. The invention also relates to the production of an effective sub-unit vaccine against IBDV utilizing the expressed antigens, as well as to the use of the expressed antigens in diagnostic tests, assays and the like.Type: GrantFiled: June 23, 1992Date of Patent: April 25, 2000Assignee: Commonwealth Scientific and Industrial Research OrganizationInventors: Ahmed Abdullah Azad, Peter John Hudson, Kevin John Fahey
-
Patent number: 5849575Abstract: A recombinant DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of IBDV RNA, particularly the IBDV RNA segment of approximately 3400 b.p. In particular, a DNA molecule coding for all or a part of at least one structural protein of IBDV, for example, the 32 Kd and/or the 41/37 Kd structural proteins. Synthetic peptides or polypeptides, and fused polypeptides, prepared by expression of host cells containing these DNA molecules are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: December 15, 1998Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Ahmed Abdullah Azad, Peter John Hudson, Kevin John Fahey
-
Patent number: 5844094Abstract: A target-binding polypeptide having (a) a stable core polypeptide region (SCR); and (b) at least one target-binding region (TBR), in which the target-binding region(s) are covalently attached to the SCR and which have optionally been subjected to a maturation step in order to modify the specificity, the affinity or the avidity of binding to the target. The polypeptides may self associate to form stable dimers, aggregates or arrays. The polypeptides of the invention have utility in the diagnostic, therapeutic, predictive or preventative fields of the pharmaceutical and health care industries, as well as more general application in the detection and assay of chemical entities.Type: GrantFiled: May 30, 1995Date of Patent: December 1, 1998Assignee: Commonwealth Scientific and Industrial Research OrganizationInventors: Peter John Hudson, Maria Lah, Alex Andrew Kortt, Robert Alexander Irving, John Leslie Atwell, Robyn Louise Malby, Barbara Elaine Power, Peter Malcolm Colman